{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:23:32Z","timestamp":1790447012755,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This post hoc analysis of the randomized, placebo\u2010controlled N\u2010MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B\u2010cell subsets and aquaporin\u20104 immunoglobulin G (AQP4\u2010lgG) titers and attacks. Among participants receiving placebo, CD20\n                    <jats:sup>+<\/jats:sup>\n                    and CD27\n                    <jats:sup>+<\/jats:sup>\n                    B\u2010cell counts were modestly increased from the pre\u2010attack visit to attack; plasmablast\/plasma cell gene signature was increased from baseline to the pre\u2010attack visit (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.016) and from baseline to attack (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009). With inebilizumab treatment, B\u2010cell subset counts decreased and did not increase with attacks. No difference in change of AQP4\u2010IgG titers from baseline to time of attack was observed.\n                  <\/jats:p>","DOI":"10.1002\/acn3.52171","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T13:24:10Z","timestamp":1725283450000},"page":"2792-2798","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["B cell and aquaporin\u20104 antibody relationships with neuromyelitis optica spectrum disorder activity"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3346-1394","authenticated-orcid":false,"given":"Jeffrey L.","family":"Bennett","sequence":"first","affiliation":[{"name":"Departments of Neurology and Ophthalmology Programs in Neuroscience and Immunology, University of Colorado School of Medicine, Anschutz Medical Campus  Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-5584","authenticated-orcid":false,"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[{"name":"Neurology, Laboratory Medicine and Pathology Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6378-0070","authenticated-orcid":false,"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Research Center Max Delbrueck Center for Molecular Medicine and Charit\u00e9 \u2013 Universit\u00e4tsmedizin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-8419","authenticated-orcid":false,"given":"Ho Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology Research Institute and Hospital of National Cancer Center  Goyang Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7667-9748","authenticated-orcid":false,"given":"Sarosh R.","family":"Irani","sequence":"additional","affiliation":[{"name":"Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences University of Oxford  Oxford UK"},{"name":"Department of Neurology Mayo Clinic  Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"O'Connor","sequence":"additional","affiliation":[{"name":"Department of Neurology and Immunobiology Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina R.","family":"Patterson","sequence":"additional","affiliation":[{"name":"Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA)  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Smith","sequence":"additional","affiliation":[{"name":"Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA)  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Gunsior","sequence":"additional","affiliation":[{"name":"Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA)  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanette","family":"Mittereder","sequence":"additional","affiliation":[{"name":"Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA)  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Rees","sequence":"additional","affiliation":[{"name":"Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA)  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cimbora","sequence":"additional","affiliation":[{"name":"Horizon Therapeutics (now Amgen Inc., Thousand Oaks, California, USA)  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-2533","authenticated-orcid":false,"given":"Bruce A. C.","family":"Cree","sequence":"additional","affiliation":[{"name":"UCSF Weill Institute for Neurosciences, Department of Neurology University of California San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418761697"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017385108"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200059"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000727"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.08.005"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn240"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy010"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2121804119"},{"key":"e_1_2_10_10_1","volume-title":"Prescribing Information","author":"UPLIZNA\u2122 (inebilizumab\u2010cdon)","year":"2020"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211047223"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515620934"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104321"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38194"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000759"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083036"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-266536"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-022-01454-0"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205233"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.03.034"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51911"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26067"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330412"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742\u20102094\u20105\u201022"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.52171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T13:04:42Z","timestamp":1730120682000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.52171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1002\/acn3.52171"],"URL":"https:\/\/doi.org\/10.1002\/acn3.52171","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"2023-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}